These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 8000691)

  • 1. [Relations between nonspecific bronchial hyperreactivity, diurnal variation of peak expiratory flow and medication requirements in patients with mild asthma].
    Prieto L; Gutiérrez V; Bertó JM; Camps B; Pérez MJ
    Arch Bronconeumol; 1994 Nov; 30(9):433-9. PubMed ID: 8000691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between airway responsiveness and peak expiratory flow variability in subjects with allergic rhinitis.
    Prieto L; Gutiérrez V; Bertó JM; Tornero C; Camps B; Pérez MJ
    Ann Allergy Asthma Immunol; 1995 Sep; 75(3):273-9. PubMed ID: 7552931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Persistence of airway obstruction and hyperresponsiveness in subjects with asthma remission.
    Boulet LP; Turcotte H; Brochu A
    Chest; 1994 Apr; 105(4):1024-31. PubMed ID: 8162720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Variability of peak expiratory flow rate in allergic rhinitis and mild asthma: relationship to maximal airway narrowing.
    Prieto L; Gutiérrez V; Morales C; Perpiñan J; Inchaurraga I
    Ann Allergy Asthma Immunol; 1998 Feb; 80(2):151-8. PubMed ID: 9494447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Maximal response plateau to methacholine as a reliable index for reducing inhaled budesonide in moderate asthma.
    Prieto L; Gutiérrez V; Morales C
    Eur Respir J; 1999 Jun; 13(6):1236-44. PubMed ID: 10445596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The protective effect of salbutamol inhaled using different devices on methacholine bronchoconstriction.
    Giannini D; Di Franco A; Bacci E; Dente FL; Taccola M; Vagaggini B; Paggiaro P
    Chest; 2000 May; 117(5):1319-23. PubMed ID: 10807817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of long-term salmeterol therapy compared with as-needed albuterol use on airway hyperresponsiveness.
    Rosenthal RR; Busse WW; Kemp JP; Baker JW; Kalberg C; Emmett A; Rickard KA
    Chest; 1999 Sep; 116(3):595-602. PubMed ID: 10492259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peak flow variation in childhood asthma: correlation with symptoms, airways obstruction, and hyperresponsiveness during long-term treatment with inhaled corticosteroids. Dutch CNSLD Study Group.
    Brand PL; Duiverman EJ; Waalkens HJ; van Essen-Zandvliet EE; Kerrebijn KF
    Thorax; 1999 Feb; 54(2):103-7. PubMed ID: 10325912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regular inhaled beta agonist in asthma: effects on exacerbations and lung function.
    Taylor DR; Sears MR; Herbison GP; Flannery EM; Print CG; Lake DC; Yates DM; Lucas MK; Li Q
    Thorax; 1993 Feb; 48(2):134-8. PubMed ID: 8493626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maximal airway response to methacholine in cough-variant asthma: comparison with classic asthma and its relationship to peak expiratory flow variability.
    Kang H; Koh YY; Yoo Y; Yu J; Kim DK; Kim CK
    Chest; 2005 Dec; 128(6):3881-7. PubMed ID: 16354858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proof-of-concept evaluation of trough airway hyper-responsiveness following regular racemic or levosalbutamol in genotype-stratified steroid-treated persistent asthmatic patients.
    Anderson WJ; Short PM; Williamson PA; Morrison AE; Palmer C; Tavendale R; Lipworth BJ
    Clin Sci (Lond); 2014 Jan; 126(1):75-83. PubMed ID: 23829494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypodense eosinophil number relates to clinical severity, airway hyperresponsiveness and response to inhaled corticosteroids in asthmatic subjects.
    Kuo HP; Yu TR; Yu CT
    Eur Respir J; 1994 Aug; 7(8):1452-9. PubMed ID: 7957830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diurnal change of bronchial caliber and airway responsiveness in asthmatics during long-term treatment with long-acting beta 2-agonist salmeterol.
    Dottorini ML; Tantucci C; Peccini F; Grassi V; Sorbini CA
    Int J Clin Pharmacol Ther; 1996 Oct; 34(10):438-43. PubMed ID: 8897082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationships between duration of asthma and asthma severity among children in the Childhood Asthma Management Program (CAMP).
    Zeiger RS; Dawson C; Weiss S
    J Allergy Clin Immunol; 1999 Mar; 103(3 Pt 1):376-87. PubMed ID: 10069869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Asthma symptoms and airway hyperresponsiveness are lower during treatment with nedocromil sodium than during treatment with regular inhaled albuterol.
    Wasserman SI; Furukawa CT; Henochowicz SI; Marcoux JP; Prenner BM; Findlay SR; Gross GN; Hudson LD; Myers DJ; Steinberg P
    J Allergy Clin Immunol; 1995 Feb; 95(2):541-7. PubMed ID: 7852670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced dose salbutamol in comparison with standard dosage for symptom relief in asthma.
    Yates DH; Peters MJ; Keatings V; Thomas PS; Barnes PJ
    Eur Respir J; 1995 Nov; 8(11):1847-51. PubMed ID: 8620950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circadian variation in airway responsiveness to methacholine, propranolol, and AMP in atopic asthmatic subjects.
    Oosterhoff Y; Koëter GH; De Monchy JG; Postma DS
    Am Rev Respir Dis; 1993 Mar; 147(3):512-7. PubMed ID: 8442580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Absence of diurnal variability of airway reactivity and hypoxic ventilatory drive in adolescents with stable asthma.
    Porter FL; White D; Attaway N; Miller JP; Strunk RC
    J Allergy Clin Immunol; 1999 May; 103(5 Pt 1):804-9. PubMed ID: 10329813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased peak flow variability in children with asymptomatic hyperresponsiveness.
    Gibson PG; Mattoli S; Sears MR; Dolovich J; Hargreave FE
    Eur Respir J; 1995 Oct; 8(10):1731-5. PubMed ID: 8586130
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sustained bronchoprotection, bronchodilatation, and symptom control during regular formoterol use in asthma of moderate or greater severity. The Canadian FO/OD1 Study Group.
    FitzGerald JM; Chapman KR; Della Cioppa G; Stubbing D; Fairbarn MS; Till MD; Brambilla R
    J Allergy Clin Immunol; 1999 Mar; 103(3 Pt 1):427-35. PubMed ID: 10069876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.